Nogo is identified as a novel gene whose expression is altered in heart failure and normalized upon phenotypic rescue, suggesting a potential role as a biomarker or therapeutic target.
No takes yet. Share an insight, caveat, or question.
Nogo emerges as candidate HF biomarker or target in fibroblasts; hypothesis-generating in animal models, human validation required.
Bullard et al. (2007) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: